Ligand, Ardelyx, Mango Health, and More
Summary
—Nurix of San Francisco unveiled Thursday a $25 million Series B round from Third Rock Ventures and The Column Group to advance its drug discovery work in the emerging field of protein homeostasis.Nurix is building upon work from three Bay Area academics and wants to develop small-molecule drugs that either speed up or slow down the process that marks proteins for degradation within the cell, witih implications for treating cancer and potentially autoimmune disease.—In San Francisco, Mango Health announced a $5.25 million Series A funding led by Kleiner, Perkins, Caufield & Byers and will use the proceeds for a variety of purposes.That drug is now partnered with AstraZeneca, which just paid Ardelyx a $25 million milestone triggered by the kickoff of a Phase 2b trial in hyperphosphatemia in patients with end-stage kidney disease.—Three startup companies were recognized for their innovations in connected health technologies last week during the Wireless-Life Science Alliance’s 9th Convergence Summit in downtown San Diego.
Funding
Review available funding amount, funding date, investors, and linked company information related to Ligand, Ardelyx, Mango Health, and More in the interactive ISVWorld profile.
Classifications
AskAI Classifications
LabelsLinked Companies
